Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Dana Culpepper

Physician Assistant, Medical Dothan, AL Physician Assistant

NPI 1699083501 CMS profile 10501648

107 Medical Dr, Dothan, AL 36303

Open in the dashboard

General payments

$6,544

328 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dana Culpepper of Dothan, AL is reported in the CMS Open Payments database as having received $6,544 across 328 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,426 68
2024 General $1,546 78
2023 General $1,738 89
2022 General $1,366 72
2021 General $469 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dana Culpepper
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Dana Culpepper were reported at $1,426. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Dana Culpepper Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $469 $156 $41–$563 $132
2022 $1,366 $185 $55–$649 $149
2023 $1,738 $199 $58–$717 $160
2024 $1,546 $206 $62–$740 $164
2025 $1,426 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,398 68 payments
  2. Novartis Pharmaceuticals Corporation $978 60 payments
  3. Janssen Biotech, Inc. $628 27 payments
  4. Lilly USA, LLC $540 29 payments
  5. Regeneron Healthcare Solutions, Inc. $464 19 payments
  6. Sun Pharmaceutical Industries Inc. $441 26 payments
  7. Incyte Corporation $338 11 payments
  8. Pfizer Inc. $285 14 payments
  9. Genzyme Corporation $244 13 payments
  10. LEO Pharma Inc. $218 11 payments
  11. Other $1,011 50 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,271 324 payments
  2. Education $273 4 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $779 33 payments
  2. TREMFYA $614 26 payments
  3. SKYRIZI $459 26 payments
  4. DUPIXENT Immunology $411 22 payments
  5. TALTZ $400 22 payments
  6. DUPIXENT Inflammation And Immunology $363 15 payments
  7. COSENTYX Dermatology $343 23 payments
  8. OPZELURA $338 11 payments
  9. COSENTYX Immunology $304 22 payments
  10. CIBINQO $285 14 payments
  11. Other $2,769 153 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

578

Median for Physician Assistant: 241

Drug cost

$227,157

Median for Physician Assistant: $4,110

Branded share of claims

7.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 24 $214,825
Metronidazole Generic 45 $2,406
Clobetasol Propionate Generic 54 $2,278
Fluorouracil Generic 26 $1,925
Mometasone Furoate Generic 95 $1,709
Clindamycin Phosphate Generic 27 $1,063
Ketoconazole Generic 55 $902
Triamcinolone Acetonide Generic 80 $612
Levocetirizine Dihydrochloride Generic 108 $574
Valacyclovir Valacyclovir Hcl Brand 19 $490

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$94,410

Medicare's payments for the services billed

Medicare patients

729

Average age 74

Services billed

3,137

405 women, 324 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 31%
Ischemic heart disease 25%
Chronic kidney disease 19%
Atrial fibrillation 18%
Depression 16%
COPD 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $239
$239 — —
TREMFYA
  • Janssen Biotech, Inc. $214
$214 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $155
$155 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $114
  • GENZYME CORPORATION $41
$155 — —
SKYRIZI
  • AbbVie, Inc. $151
$151 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

328 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record